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Abstract
Introduction A recent abstract presented in a breast cancer
symposium attributed the sharp decrease in female breast
cancer incidence rates from 2002 to 2003 in the Surveillance,
Epidemiology, and End Results (SEER) cancer registries of the
United States to the reduced use of hormone replacement
therapy since July 2002. However, this hypothesis does not
explain the decrease that began in 1999 in the age-standardized
incidence rate of invasive breast cancer in the nine oldest SEER
cancer registry areas, although the trend through 2003 was not
statistically significant. In this paper, we examine temporal
trends in invasive and in situ female breast cancer by age, stage,
tumor size, and estrogen receptor/progestin receptor (ER/PR)
status in the nine oldest SEER cancer registry areas and
consider the implication of these trends in relation to risk factors
and screening.
Methods We performed a joinpoint regression analysis to fit a
series of joined straight lines to the trends in age-adjusted rates
and described the resultant trends (slope) by annual percentage
change (two-sided, P < 0.05).
Results A plot of the age-specific rates of invasive breast
cancer shows a decrease in all 5-year age groups from 45 years
and above between 1999 and 2003 and sharp decreases
largely confined to ER+ tumors in age groups from 50 to 69
years between 2002 and 2003. In joinpoint analyses by tumor
size and stage, incidence rates decreased for small tumors (less
than or equal to 2 cm) by 4.1% (95% confidence interval [CI],
0.2% to 7.8%) per year from 2000 through 2003 and for
localized disease by 3.1% (95% CI, 1.2% to 5.0%) per year
from 1999 through 2003. No decrease in incidence was
observed for larger tumors or advanced-stage disease during
the corresponding periods. Rates for in situ disease were stable
from 2000 through 2003 after increasing rapidly since 1981.
Conclusion Two distinct patterns are observed in breast cancer
trends. The downturn in incidence rates in all age groups above
45 years suggests a period effect that is consistent with
saturation in screening mammography. The sharp decrease in
incidence from 2002 to 2003 that occurred in women 50 to 69
years old who predominantly, but not exclusively, had ER+
tumors may reflect the early benefit of the reduced use of
hormone replacement therapy.
Introduction
A recent abstract presented in a breast cancer symposium
suggested that the sharp decrease in female breast cancer
incidence rates from 2002 to 2003 in the Surveillance, Epide-
miology, and End Results (SEER) cancer registries of the
United States may have resulted from the reduced use of hor-
mone replacement therapy (HRT) following a July 2002 publi-
cation from the Women's Health Initiative [1]. However, the
age-standardized delay-adjusted incidence rate of invasive
breast cancer in the nine oldest SEER cancer registry areas
began to decrease in 1999, although the trend through 2003
was not statistically significant by joinpoint analysis [2]. The
recent downturn follows an 18-year period (1980 to 1998) in
which breast cancer incidence rates increased by almost
40%. Most of the increase that occurred during the 1980s
reflected increased detection of localized disease and tumors
measuring less than 2 cm in diameter and has been attributed
to the increased use of mammography [3-6]. These effects of
mammography are superimposed upon and preceded by long-
term birth cohort patterns due to generational changes in
reproductive behavior [7,8].
To characterize the recent decrease in breast cancer inci-
dence in relation to earlier secular trends, we examined
temporal trends in incidence rates by tumor size, stage, and
estrogen receptor/progestin receptor (ER/PR) status and
CI = confidence interval; ER = estrogen receptor; HRT = hormone replacement therapy; PR = progestin receptor; SEER = Surveillance, Epidemiol-
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trends for in situ breast cancer among women at least 40
years old from 1975 through 2003 by means of incidence data
from the nine oldest SEER cancer registry areas. We also
examined the age-specific incidence rates for invasive breast
cancer by 5-year age intervals. We restricted our analyses to
women at least 40 years old because regular mammography
screening does not begin before age 40 and HRT use is com-
mon after age 50.
Materials and methods
We obtained the incidence rates for invasive breast cancer
from 1975 through 2003 for women by 5-year age intervals
beginning at age 40 from the CanQues (Cancer Query Sys-
tems) database of the National Cancer Institute (Bethesda,
MD, USA), which provides delay-adjusted rates for the nine
oldest SEER cancer registries, which are comprised of five
states (Connecticut, Hawaii, Iowa, New Mexico, and Utah) and
four metropolitan areas (Atlanta, GA; Detroit, MI; San Fran-
cisco-Oakland, CA; and Seattle-Puget Sound, WA) [9]. Delay-
adjusted rates account for the expected reporting delays and
data corrections that most frequently occur in the most recent
1 to 3 years of incidence data (in this case, 2001 to 2003)
[10]. We plotted age-specific rates by 5-year age intervals and
by year of diagnosis among women at least 40 years old and
characterized the trends descriptively without requiring that
the recent trend be statistically significant. We restricted our
analyses to women at least 40 years old because regular
mammography screening does not begin before age 40 and
HRT use is common after age 50.
Information on stage at diagnosis, tumor size, and ER/PR sta-
tus in the nine oldest SEER cancer registries is available for
cases diagnosed since 1975 for stage, since 1988 for tumor
size, and since 1990 for ER/PR status [11]. We examined the
trend in breast cancer incidence rate from 1988 through 2003
according to tumor size for three categories (less than or equal
to 2 cm, 2.1 to 3.0 cm, and more than 3 cm) by means of pre-
viously published groupings for assessing the influence of
early detection and mammography use [3,5]. We also exam-
ined the incidence trend according to stage at diagnosis
(local, regional, or distant) from 1975 through 2003 and
according to ER or PR status from 1990 through 2003. These
analyses used the joinpoint model [12] and were restricted to
women age 40 and older. A joinpoint regression model fits a
series of joined straight lines on a log scale to the trends in
age-adjusted rates (2000 U.S. standard population). The
resultant trends of varying time periods were described by
annual percentage change (that is, the slope of the line seg-
ment) (two-sided, P < 0.05). Similarly, we analyzed temporal
trends in age-standardized incidence rates for in situ breast
cancer from 1975 through 2003 in women age 40 and older
in the nine SEER cancer registry areas by joinpoint analysis.
Delay-adjusted data are not available from SEER by stage,
tumor size, or ER/PR status or for in situ tumors. Therefore,
analyses by stage, tumor size, and ER/PR status and of in situ
tumors were not adjusted for delayed reporting. Incident
breast tumors in the SEER database were classified as inva-
sive or in situ according to the third edition of the International
Classification of Diseases for Oncology [13].
Table 1
Invasive and in situ breast cancer cases diagnosed in women 40 years old and above in the nine oldest SEER cancer registry areas 
of the U.S. (1975 to 2003)
Invasive In situ
Age (years) Number Percentage Number Percentage
40–44 28,893 7.3 5,902 9.9
45–49 39,696 10.1 8,719 14.6
50–54 43,107 10.9 8,885 14.8
55–59 45,470 11.5 7,690 12.9
60–64 48,011 12.2 6,878 11.5
65–69 49,652 12.6 7,003 11.7
70–74 47,139 11.9 6,207 10.4
75–79 40,886 10.4 4,689 7.8
80–84 28,378 7.2 2,559 4.3
85+ 23,659 6.0 1,305 2.2
Total (≥40) 394,891 100.0 59,837 100.0
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Results
From 1975 through 2003, 394,891 invasive and 59,837 in
situ breast cancer cases were diagnosed in women age 40
and older in the nine oldest SEER cancer registry areas of the
U.S. (Table 1). The age-specific incidence rates of invasive
breast cancer decreased in every age group of women age 45
and older between 1999 and 2003, although the magnitude
and timing of decrease varied by age (Figure 1). Among
women less than 60 years old or more than 69 years old, the
decrease generally began in 1998 or 1999. In contrast,
among women 60 to 64 years old and 65 to 69 years old, all
of the decrease occurred from 2002 to 2003, the most recent
year for which data are available. The largest percentage
decreases from 2002 to 2003 occurred in women 55 to 59
years old (11.3%), 60 to 64 years old (10.6%), and 65 to 69
years old (14.3%).
In joinpoint analysis by tumor stage and size, the decrease in
breast cancer incidence rates was confined to small tumors
(less than or equal to 2 cm) and local and regional disease
(Figure 2). Statistically significant decreases during the time
period 1999/2000 through 2003 were observed for tumors
less than or equal to 2 cm (annual percentage decrease,
4.1%; 95% confidence interval [CI], 0.2% to 7.8%) and for
localized disease (annual percentage decrease, 3.1%; 95%
CI, 1.2% to 5.0%). Incidence rates for in situ breast cancer
stabilized from 1999 through 2003 after increasing by more
than 6.6% (95% CI, 5.6% to 7.6%) per year since 1981 (Fig-
ure 2).
Figure 3 shows trends in the age-standardized incidence rates
by ER or PR status. Incidence rates for ER+ tumors signifi-
cantly increased by approximately 3% (95% CI, 2.0% to
3.9%) per year from 1990 to 2000 and then dropped sharply
by 9.1% between 2002 and 2003. In contrast, the incidence
rates for ER- tumors significantly decreased by 1.1% (95% CI,
0.6% to 1.7%) per year from 1990 to 2003. The decrease was
largest (4.8%) between 2002 and 2003. Similar to the inci-
dence rates for ER+ tumors, those for PR+ tumors increased
significantly by 2.9% (95% CI, 2.0 to 3.8) per year from 1990
to 2000 and then sharply decreased by 9.1% between 2002
and 2003. The opposite was observed for PR- tumors, which
according to joinpoint analysis continued to increase by 1.2%
(95% CI, 0.5 to 1.9) per year throughout the entire time inter-
val from 1990 to 2003. However, in the 1-year interval from
2002 to 2003, the incidence rate for PR- tumors decreased by
6.9%. Further analysis by 5-year age interval showed that the
decrease in the incidence rates from 2002 to 2003 was much
larger in women 50 to 69 years old for ER+ and PR+ than for
ER- and PR- tumors. For example, from 2002 to 2003, the inci-
dence rate in women 65 to 69 years old decreased by 20%
for ER+ and PR+ tumors compared to an increase of 2% for
ER- tumors and a decrease of 9% for PR- tumors.
The SEER data also reflect improvements in tumor staging,
measurement, and ER/PR assays over the 30-year duration of
the program. The incidence of breast cancer with unknown
stage at diagnosis decreased from 13.5 cases per 100,000 in
1975 to 4.9 in 2003 among women age 40 and older. Simi-
larly, between 1988 and 2003, the incidence of tumors of
unspecified size decreased from 35.9 cases per 100,000 to
17.5. Between 1990 and 2003, the incidence rate of tumors
with unspecified ER or PR status decreased from more than
80 cases per 100,000 in 1990 to approximately 40 cases per
100,000 in 2003.
Discussion
We find two distinct patterns with respect to recent trends in
breast cancer incidence in the nine oldest SEER cancer reg-
istry areas. First, a downturn in the incidence rates began in
1998/1999 in all age groups of women 45 years old and
above. This pattern is most consistent with a calendar period
Figure 1
Trends in age-specific invasive breast cancer incidence rates among  women 40 years old and above, 1975 to 2003 Trends in age-specific invasive breast cancer incidence rates among 
women 40 years old and above, 1975 to 2003. Rates are adjusted for 
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effect relating to the saturation or plateau in screening mam-
mography as described below. A second trend is the sharp
decrease in breast cancer incidence among women 50 to 69
years old between 2002 and 2003 which may represent an
early benefit of the reduced use of HRT.
Several aspects of the downturn in incidence rates which
began in 1998/1999 are consistent with a period effect due
to a plateau in screening mammography. First, the deceases
are observed in multiple age groups at roughly the same time
and are greatest for small tumors (less than or equal to 2 cm)
and localized or in situ disease that are most commonly
detected by mammography [14]. Second, the timing of the
decrease coincides with a plateau in mammography use as
measured by national surveys. The percentage of women age
40 and older who report that they had a mammogram within
the past 2 years has essentially stabilized since 1999 after
increasing from 29% in 1987 [15]. According to data from the
National Health Interview Survey [15], this percentage was
70.3% in 1999, 70.4% in 2000, and 69.5% in 2003. Typically,
incidence rates decrease when the penetrance of a screening
test reaches a plateau due to a reduced pool of undiagnosed
prevalent cases.
The rapidity of the decrease in breast cancer incidence rates
after the dramatic reduction in the use of HRT which followed
the publication of the Women's Health Initiative in July 2002
[16-18] is not inconsistent with the relationship being caused
by withdrawal of HRT. Sudden withdrawal of a promoting
agent, such as HRT, could slow the growth of tumors that are
below the detection limit of mammography and decrease inci-
dence at least in the short term. The observed decrease was
largest in women 50 to 69 years old, in whom HRT use is most
common, and predominantly (but not entirely) involved ER+
tumors [1]. However, the recent decrease in HRT use cannot
account for the reduction in breast cancer incidence that
occurred before 2002 or for the decreased incidence in
women age 75 and older. If the decrease in ER+ tumors from
2002 to 2003 in women 50 to 74 years old were entirely due
to the reduction in HRT use, the maximum HRT contribution to
the decrease would be 75%.
Delay-adjusted data are not available by stage, tumor size, or
ER/PR status or for in situ breast tumors. Therefore, our anal-
yses by stage, tumor size, and ER/PR status and for in situ
breast tumors did not account for delayed reporting. Delayed
reporting would increase rather than decrease the incidence
of localized, small, or in situ tumors. We reanalyzed the data
by stage and tumor size after accounting for delayed reporting,
Figure 2
Trends in age-standardized invasive breast cancer rates among women 40 years old and above Trends in age-standardized invasive breast cancer rates among women 40 years old and above. (a) Trend by tumor size (1988 to 2003). (b) Trend 
by stage (1975 to 2003). (c) Trend for in situ breast cancer rates (1975 to 2003). Solid lines represent observed rates and dashed lines fitted rates.Available online http://breast-cancer-research.com/content/9/3/R28
Page 5 of 6
(page number not for citation purposes)
assuming that delayed reporting for each tumor size and stage
category was similar to that of all invasive cases combined. In
this sensitivity analysis, the decreases in incidence rates over
the most recent 4 to 5 data years were only slightly attenuated
for tumors less than or equal to 2 cm (from 4.1% to 3.6% per
year) and for localized disease (from 3.1% to 2.8%), differ-
ences that are too small to invalidate the findings. Delayed
reporting would cause our analysis to underestimate the inci-
dence of in situ tumors for the most recent 1 to 2 years but
cannot account for the incidence plateau that began in 1998.
It is also noteworthy that over the study period the improve-
ments in tumor staging, measurements, and ER/PR assays
may have contributed in part to the temporal increase in the
rates for specified types of breast cancer.
Conclusion
We observe two distinct patterns in recent trends in breast
cancer incidence rates in the nine oldest SEER cancer registry
areas. First, the downturn in incidence rates in multiple age
groups of women 45 years old and above suggests a period
effect that is consistent with saturation in screening mammog-
raphy. Second, the sharp decrease in incidence from 2002 to
2003 in women 50 to 69 years old, which is larger in ER+/PR+
tumors than in ER-/PR-  tumors, may reflect early conse-
quences of the reduced use of HRT.
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